EPS for Trillium Therapeutics Inc. (TRIL) Expected At $-0.89; Joshua Gold Resources (BIO)’s Sentiment Is 0.78

February 21, 2018 - By Marie Mckinney

Analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) to report $-0.89 EPS on March, 9.They anticipate $0.03 EPS change or 3.49% from last quarter’s $-0.86 EPS. After having $-0.84 EPS previously, Trillium Therapeutics Inc.’s analysts see 5.95% EPS growth. It closed at $7.05 lastly. It is down 39.86% since February 21, 2017 and is downtrending. It has underperformed by 56.56% the S&P500.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $7.46 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 312.99 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on February, 27 after the close. They expect $1.28 EPS, up 2.40% or $0.03 from last year’s $1.25 per share. BIO’s profit will be $38.03 million for 49.03 P/E if the $1.28 EPS becomes a reality. After $0.91 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 40.66% EPS growth.

The stock decreased 0.04% or $0.1 during the last trading session, reaching $251.01. About 2,768 shares traded. Bio-Rad Laboratories, Inc. (BIO) has risen 53.78% since February 21, 2017 and is uptrending. It has outperformed by 37.08% the S&P500.

Tikvah Management Llc holds 13% of its portfolio in Bio-Rad Laboratories, Inc. for 138,007 shares. Beaconlight Capital Llc owns 67,874 shares or 7.96% of their US portfolio. Moreover, Sector Gamma As has 3.71% invested in the company for 109,440 shares. The New York-based Claar Advisors Llc has invested 3.48% in the stock. Hitchwood Capital Management Lp, a New York-based fund reported 350,000 shares.

Ratings analysis reveals 50% of Bio-Rad Labs’s analysts are positive. Out of 2 Wall Street analysts rating Bio-Rad Labs, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. BIO was included in 2 notes of analysts from October 13, 2016. The rating was initiated by CL King on Thursday, October 13 with “Buy”. Deutsche Bank initiated it with “Hold” rating and $195.0 target in Wednesday, January 18 report.

Since January 1, 0001, it had 0 insider buys, and 2 sales for $1.52 million activity.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company has market cap of $90.57 million. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. It currently has negative earnings. The Company’s product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase.

Among 3 analysts covering Trillium Therapeutics (NASDAQ:TRIL), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Trillium Therapeutics had 5 analyst reports since August 26, 2015 according to SRatingsIntel. As per Thursday, December 14, the company rating was maintained by H.C. Wainwright. On Thursday, June 8 the stock rating was maintained by Ladenburg with “Buy”. Cowen & Co maintained the stock with “Buy” rating in Wednesday, July 5 report. The company was upgraded on Wednesday, August 26 by Zacks.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: